Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
70 participants
INTERVENTIONAL
2022-08-01
2023-10-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Dural Puncture Epidural and Standard Epidural Anesthesia Techniques in Elective Cesarean Deliveries
NCT07295080
Effect of Higher Volume and Lower Dose on Analgesic Quality During Labor Analgesia With Dural Puncture Epidural
NCT06156709
Comparison of Labor Analgesia Between Modified Combined Spinal-Epidural and Dural Puncture Epidural Techniques
NCT03258879
Dural Puncture Epidural Versus Epidural Anesthesia for Cesarean Delivery
NCT03915574
Sterile Water Injections For Pain Relief İn Labor
NCT02697994
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants will randomly be divided into 2 equal groups. Immediately before epidural placement, subjects will be marked a VAS score during an active contraction. All subjects will have an intravenous catheter placed and be monitored with NST, noninvasive blood pressure and pulse oximetry.
The epidural space will be identified by a loss of resistance technique to saline. CSF flow will be observed at L3-L4 or L4-L5 level by puncturing the dura with a 27 G needle before inserting the epidural catheter. A combined spinal epidural set with 18 G Tuohy needle will be used in both groups. In the first group, 20 mL of 0.125% bupivacaine + 2 mcg/mL fentanyl solution and in the second group, 20 mL of 0.0625% bupivacaine + 2 mcg/mL fentanyl solution will be administered as the first dose through the epidural catheter. Then, the visual analog scale (VAS) score will be aimed to be below 4 in both groups. Patients with a VAS score of 4 or higher 15 minutes after the first dose received, an additional 10 mL dose of the same solution will be given. An additional 10 mL dose also will be administered when the VAS score is 4 or higher until crowning.
Before the epidural catheter placed; age, weight, height, blood pressure of the participants, gestational week, use of oxytocin during delivery, cervical dilatation amount before the procedure and fetal heart rate will be recorded. After each dose of administration, whether maternal hypotension, fetal bradycardia, pruritus, nausea-vomiting or motor block development will be monitored. The total amount of drug administered through the epidural catheter, the time between applications, and the number of bolus doses administered will also be recorded.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
High concentration
Epidural analgesia with 20 mL of 0.125% bupivacaine + 2 mcg/mL fentanyl solution
Dolantin
If VAS score is more than 4 even after additional dose, use dolantin 1 mg/kg
Paracetamol
If VAS score is more than 4 even after dolantin 1 mg/kg, 10 mg/kg paracetamol IV
Low concentration
Epidural analgesia with 20 mL of 0.0625% bupivacaine + 2 mcg/mL fentanyl solution
Dolantin
If VAS score is more than 4 even after additional dose, use dolantin 1 mg/kg
Paracetamol
If VAS score is more than 4 even after dolantin 1 mg/kg, 10 mg/kg paracetamol IV
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dolantin
If VAS score is more than 4 even after additional dose, use dolantin 1 mg/kg
Paracetamol
If VAS score is more than 4 even after dolantin 1 mg/kg, 10 mg/kg paracetamol IV
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* with cervical dilatation between 4-6 cm, demanding epidural analgesia during spontaneous vaginal delivery
Exclusion Criteria
* gestational hypertension
* gestational diabetes
* preeclampsia/ celmpsia
* contraindications for neuraxial block
* infection
* coagulation disorders
* severe hypovolemia
* sepsis
* neurological deficit
* cardiac valve stenosis or hypertrophic obstructive cardiomyopathy
* Women with fetal malpresentation and fetal anomaly
18 Years
45 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medipol University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pelin Karaaslan
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pınar Uçar
Role: PRINCIPAL_INVESTIGATOR
Medipol University
Emine Uzunoğlu
Role: STUDY_CHAIR
Medipol University
Pelin Karaaslan
Role: STUDY_DIRECTOR
Medipol University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Istanbul Medipol University
Istanbul, Bağcılar, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KARAASLANP
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.